Original Article

European Journal of Nuclear Medicine and Molecular Imaging

, Volume 36, Issue 3, pp 347-353

Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study

  • Andrew M. ScottAffiliated withCentre for PET, Austin HospitalLudwig Institute for Cancer Research, Austin Hospital Email author 
  • , Dishan H. GunawardanaAffiliated withCentre for PET, Austin Hospital
  • , Joseph WongAffiliated withSouthern X-Ray Clinics, The Wesley Hospital
  • , Ian KirkwoodAffiliated withDepartment of Nuclear Medicine and PET, Royal Adelaide Hospital
  • , Rodney J. HicksAffiliated withCentre for Molecular Imaging, Peter MacCallum Cancer Centre
  • , Ivan Ho ShonAffiliated withDepartment of Nuclear Medicine & PET, Liverpool Hospital
  • , Jayne E. RamshawAffiliated withAustralian and New Zealand Association of Physicians in Nuclear Medicine
  • , Peter RobinsAffiliated withWA PET/Cyclotron Service, Sir Charles Gairdner Hospital

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Purpose

Positron emission tomography (PET) was evaluated in low-grade non-Hodgkin lymphoma (NHL) to determine its impact on staging and management and to compare PET and gallium scans.

Methods

PET resulted in management plan changes in 74 patients with untreated low-grade NHL stages I to III. Patient outcomes to 12 months were documented.

Results

PET identified additional lesions in 50% of patients, led to a change in stage in 32%, and had a significant impact on management in 34%. Inferior progression-free survival was noted in patients with additional lesions detected by PET (p=0.001) and in the 28% of patients upstaged by PET to stage III or IV (p=0.024). In a subset of 16 patients undergoing both PET and gallium scans, PET was found to be superior.

Conclusion

PET has a major role in the management of low-grade NHL in addition to its proven role in aggressive lymphoma.

Keywords

PET Gallium Low-grade lymphoma